Efficacy and Safety of Compound Kushen Injection on Patients with Advanced Colon Cancer: A Meta-Analysis of Randomized Controlled Trials

Lixiu Yu,1 Ying Zhou,1 Yu Yang,1 Furong Lu,2 and Yeqin Fan3

1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
3School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Correspondence should be addressed to Lixiu Yu; yxl20515@163.com

Received 4 February 2017; Accepted 10 October 2017; Published 12 November 2017

Objective. The efficacy and safety of Compound Kushen Injection (CKI) on advanced colon cancer remain controversial. We undertook a systematic meta-analysis of randomized controlled clinical studies on this issue. Methods. A comprehensive literature search was conducted by searching the following electronic databases: PubMed, Cochrane, Chinese Biological Medical disc, Chinese National Knowledge Infrastructure, and Wan-Fang Database in China by the end of January 31, 2017, without language restriction. Meta-analysis was performed by using the random effects model to estimate the summary odd ratio (OR) with 95% confidence interval (CI) according to the study design. Stata 12.0 software was used for data analysis. The heterogeneity, sensitivity, and publication bias were assessed, respectively. Results. A total of 14 trials met the inclusion criteria in present meta-analysis. The results suggested that CKI combined with chemotherapeutic drugs was favorable for the treatment of advanced colon cancer and could improve the patients’ life quality. Funnel plot analysis and Egger’s test suggested that there was not significant publication bias, and the sensitivity analysis indicated stable results. Conclusion. The current evidence suggested that CKI is favorable to improve the efficacy of chemotherapeutic drugs in patients with advanced colon cancer.

1. Introduction

Colon cancer is a malignant tumor of digestive tract and is considered to be the third most common cancer in the world [1, 2]. It is generally known that balanced diet is important to maintain health. While, in recent years, with the improvement of people’s living standard, most people eat more greasy food than coarse grains or dietary fiber in daily life, which increased the risk of colon cancer [3, 4]. In addition, the symptom of early colon cancer is relatively hidden and not easy to diagnose that many patients are being diagnosed at advanced stage [5, 6]. FOLFOX (oxaliplatin, 5-FU, and leucovorin) adjuvant chemotherapy remains the backbone of colon cancer patients. It can improve survival rate of colon cancer patients [7, 8]. However, chemotherapeutic drugs often decreased the immune function of the patients and produced a variety of adverse drug reactions (ADRs) such as nausea, vomiting, thrombocytopenia, and liver function damage, which seriously affected the patient’s life quality [9, 10]. The efficacy and safety of chemotherapeutic drugs need to be improved.

In recent years, an increasing number of studies have proved that the traditional Chinese medicine (TCM), especially in combination with chemotherapeutic drugs, played an important role in improving the effectiveness and immunomodulation [11, 12]. Furthermore, TCM can reduce the toxic and side effects caused by chemotherapy medicament [13–15]. Compound Kushen Injection (CKI) is one of the commonly used TCMs in China, which is mainly extracted from two different Chinese herbs: Kushen...
(Radix sophorae flavescentis) and Baituling (Rhizoma smilacis glabrae) [16, 17]. As CKI contains various active components such as matrine, oxymatrine, and sophoridine, it exhibits a variety of pharmacological activities, including anti-inflammatory, antiallergic, antiviral, antibacterial, and especially anticancer activities [18, 19]. In addition, previous studies confirmed that CKI could enhance metabolism and blood circulation, enhance the patient’s immunity, relieve pains, and reduce some disoperation of chemotherapeutics [27, 28].

As we know, side effects such as leukopenia, gastrointestinal adverse reactions, alopecia, and bone marrow depressions are common after chemotherapy [16]. How to reduce the adverse reactions and improve the quality of life of patients has become a concern of researchers. Investigators have proved the attenuation effect of the CKI to the toxic and side effects during chemotherapy [29]. And it has been proved that the effective components of matrine and oxymatrine are small molecule drug used in humans for the treatment of tumors with little adverse effects [30]. In addition, CKI did not produce damaging effects on normal cells and could increase white blood cell count and enhance immune function compared to other chemotherapeutic drugs [31, 32]. A systematic meta-analysis was conducted to evaluate the effect of CKI on relieving cancer-related pain [16]. The findings showed that CKI plus chemotherapy could relieve cancer-related pain better than chemotherapy except for colorectal cancer. However, for all we know, there was not a meta-analysis to evaluate efficacy and safety of CKI for advanced colon cancer. In this study, we aimed to carry out a meta-analysis to assess the efficacy and safety of CKI on this issue.

2. Methods

2.1. Literature Search. We searched the online databases including PubMed, Cochrane, Chinese Biological Medical disc (CBM), Chinese National Knowledge Infrastructure (CNKI), and Wan-Fang Database in China without language restrictions until January 31, 2017. The key words used in this search were as follows: “colon cancer/colonic carcinoma (MeSH Terms), “Kushen”, “Radix sophorae flavescentis”, “Baituling”, “Rhizoma smilacis glabrae”, “CKI” and “chemotherapy”. Furthermore, hand searching techniques were also used to identify the appropriate studies and just full length original articles were included. Studies which have only reported abstracts were excluded.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria were as follows: patients with advanced colon cancer (stage III-IV colon cancer) which was confirmed by pathologic or histologic investigation and who had no hypertension, hyperthyroidism, malignant tumor, or other diseases; patients received CKI combined with chemotherapeutic drugs versus patients just received chemotherapeutic drugs; randomized controlled trials (RCTs); outcome assessment included effect analysis such as complete remission, partial remission, quality of life (assessed by Karnofsky Performance Status (KPS) scoring criteria), and adverse drug reactions. The exclusion criteria were (i) reviews, nonclinical studies; (ii) non-RCTs; (iii) controlled interventions with other Chinese herbs therapies or acupuncture; and (iv) no outcome measurements or duplicated citations.

2.3. Data Extraction. Data was extracted independently by two investigators (Yeqin Fan and Lixiu Yu) according to the above inclusion and exclusion criteria. Any discrepancy between the reviewers was solved by discussion. General information of the eligible studies including first author’s name, published year, cases of participants in CKI combined with chemotherapeutic drugs group and chemotherapeutic drugs alone group, age, chemotherapy regimen, immune function, and effects of CKI treatment were selected from each article. Specific data such as effect analysis and ADR were also extracted carefully.

2.4. Data Synthesis and Analysis. Statistical analyses were conducted by using Stata 12.0 software (StataCorp LP, College Station, TX). The efficacy and safety of CKI on patients with advanced colon cancer were measured by pooled odd ratio (OR) with 95% confidence interval (CI) at the end of treatment course. The Cochran Q statistic and \( I^2 \) were introduced to evaluate the heterogeneity of eligible studies. If substantial heterogeneity exists \( (I^2 > 50\%) \), the estimated outcomes across eligible studies were calculated by random effect model [44]. Otherwise fixed effect model was preferred [45]. And a statistical test with \( p < 0.05 \) was considered significant. For detection of potential publication bias, funnel plots and Egger’s tests were introduced \( (p < 0.05 \) suggested statistical significance) [46]. Meanwhile, to assess the robustness of the combined effects, sensitivity analysis was also performed, which were performed by sequential removal of each study.

3. Results

3.1. Search Results. The process of selection of the included studies was illustrated in Figure 1. A total of 236 citations were found through online databases and manual searching. After removing the duplicates, 116 articles were left. Then 84 studies were excluded by reviewing the titles and abstracts based on predetermined criteria. After further review, 32 articles were chosen for full text evaluation. By thoroughly reading the full text 18 articles were also excluded based on the inclusion criteria. Finally, fourteen published RCTs [27, 29, 31, 33–43] with 1145 advanced colon cancer patients were included in the present meta-analysis.

3.2. Characteristics of Identified Studies. The baseline characteristics of all included studies are presented in Table 1.
| Studies                  | Cases | Effect (CR + PR) | Chemotherapeutic drugs | Age (year) | ADR          | Immune function                        |
|-------------------------|-------|------------------|------------------------|------------|--------------|----------------------------------------|
| Wang and Liu, 2015 [27] | 32    | 21 (3/18)       | OXA + CF + 5-FU + CKI 12 ml/d | 21–72      | 19 (1/18)   | 1, 3, 5, 6, 7                          |
| Tao and Xu, 2013 [29]   | 74    | 23 (7/16)       | OXA + CF + 5-FU         | 49–74      | 19 (1/11)   | 1, 3, 5, 6, 7, 11, 12                  |
| Li et al., 2015 [31]    | 26    | 20 (13/7)       | OXA + CF + 5-FU + CKI 15 ml/d | 45–68      | 1, 3, 5, 6, 7, 11, 12                  |
| Kang et al., 2015 [33]  | 52    | 13 (0/13)       | OXA + CF + 5-FU + CKI 20 ml/d | 66.31 ± 7.29 | 2, 4, 6     | —                                      |
| Gao and Feng, 2014 [34] | 40    | 12 (3/9)        | OXA + CF + 5-FU + CKI 15 ml/d | 31–73      | 1, 3, 4, 5, 8, 9                        |
| R. R. Li and H. S. Li, 2015 [35] | 35 | 15 (1/4)      | IV + CF + 5-FU + CKI 15 ml/d | 41–63      | 1, 3, 4, 5, 6, 7                        |
| Liu, 2014 [36]          | 52    | 10 (3/7)        | OXA + CF + 5-FU + CKI 20 ml/d | 38–76      | 1, 3, 4, 5, 7                           |
| Qi, 2016 [37]           | 36    | 1 (1/7)         | OXA + CF + 5-FU + CKI 15 ml/d | 42–68      | 1, 3, 4, 5, 7                           |
| Zheng et al., 2011 [38] | 36    | 8 (1/7)         | OXA + CF + 5-FU + CKI 15 ml/d | 40–69      | 1, 3, 4, 5, 7                           |
| Xu, 2014 [39]           | 30    | 18 (8/10)       | OXA + CF + 5-FU + CKI 15 ml/d | 45–78      | 1, 3, 4, 5, 7                           |
| Wang et al., 2015 [40]  | 33    | 12 (1/11)       | OXA + CF + 5-FU          | 51.8 ± 5.9 | 1, 3, 5, 6, 7                           |
| Ren et al., 2014 [41]   | 60    | 33 (8/32)       | OXA + CF + CKI 12 ml/d   | 33–76      | 2, 4, 6, 7                              |
| Fang and Zhang, 2012 [42]| 36   | 21 (9/12)       | OXA + CF + 5-FU + CKI 12 ml/d | 17–70      | 1, 3, 4, 5, 7                           |
| Xiang and Liu, 2016 [43]| 39    | 15 (3/12)       | OXA + RA + CKI 20 ml/d   | 29–75      | 1, 3, 5, 6, 12                           |

**Table 1: Baseline characteristic of eligible articles.**

**Note.** T: Compound Kushen Injection combined with chemotherapeutic drugs group; C: chemotherapeutic drugs alone group; CR: complete remission; PR: partial remission; 1: nausea and vomiting; 2: myelosuppression; 3: leukopenia; 4: digestive tract reaction (Diarrhea); 5: thrombocytopenia; 6: liver injury; 7: renal injury; 8: neurotoxicity; 9: anaemia.; 10: oral mucositis; 11: hypochromia; 12: peripheral phlebitis.
Table 2: Methodological quality evaluation of eligible trials.

| Studies                  | Random | Blinding | Incomplete data | Allocation | Selective reporting | Other bias |
|--------------------------|--------|----------|-----------------|------------|---------------------|------------|
| Wang and Liu, 2015       | Yes    | No       | No              | NA         | No                  | NR         |
| Tao and Xu, 2013         | Yes    | No       | No              | NA         | No                  | NR         |
| Li et al., 2015          | Yes    | No       | No              | NA         | No                  | NR         |
| Kang et al., 2015        | Yes    | No       | No              | NA         | No                  | NR         |
| Gao and Feng, 2014       | Yes    | No       | No              | NA         | No                  | NR         |
| R. R. Li and H. S. Li, 2015 | Yes  | No       | No              | NA         | No                  | NR         |
| Liu, 2014                | Yes    | No       | No              | NA         | No                  | NR         |
| Qi, 2016                 | Yes    | No       | No              | NA         | No                  | NR         |
| Zheng et al., 2011       | Yes    | No       | No              | NA         | No                  | NR         |
| Xu, 2014                 | Yes    | No       | No              | NA         | No                  | NR         |
| Wang et al., 2015        | Yes    | No       | No              | NA         | No                  | NR         |
| Ren et al., 2014         | Yes    | No       | No              | NA         | No                  | NR         |
| Fang and Zhang, 2012     | Yes    | No       | No              | NA         | No                  | NR         |

Note: NA: not available; NR: not reported.

Figure 1: The process of selection of the eligible studies.

All these clinical trials were RCTs and performed in China. The dates of publication were between 2013 and 2016. The stages of the patients with colon cancer were advanced stages. A total of 11 studies used CKI plus Oxaliplatin (OXA) + Calcium Folinate (CF) + 5-Fluorouracil (5-FU) regimen. The rest of the three studies were used CKI plus OXA + CF, OXA + Raltitrexed (RA), Irinotecan (IR) + CF + 5-FU, respectively. Three studies [31, 36, 39] reported numbers of patients achieved improvement of quality of life. Eleven clinical trials [27, 29, 33–35, 37, 38, 40–43] reported ADR of the patients. The methodological quality evaluation of eligible trials was listed in Table 2.

3.3. Meta-Analysis Results

3.3.1. Efficacy of CKI Combined with Chemotherapeutic Drugs. The meta-analysis of all the included studies indicated that in the CKI combined with chemotherapeutic drugs group 382 of 581 patients reached complete remission (CR) or partial remission (PR), while 255 of 564 subjects achieved CR or PR in the chemotherapy alone group. Compared with chemotherapy alone, CKI combined with chemotherapy had a favorable effect with OR = 1.48 (95% CI: 1.21–1.80), $I^2 = 0\%$, $p = 0.961$ demonstrated that the heterogeneity across the included studies was not significant and then the fixed effect model was used in this pooled analysis (Figure 2). Furthermore, in the subgroup analysis, we found that CKI combined with chemotherapeutic drugs had significant association with CR and PR. The integrated OR for CR was 1.76 (95% CI: 1.28–2.43, $I^2 = 0\%$, $p = 0.998$), and the pooled OR for PR was 1.35 (95% CI: 1.08–1.70; $I^2 = 0\%$, $p = 0.885$). These findings indicated that CKI in combination with chemotherapeutic drugs had better effects than chemotherapeutic drugs alone.

3.3.2. Life Quality Improvement. Three articles [31, 36, 39] reported the quality of life improvement at the end of the treatment. The results indicated that significant heterogeneity ($I^2 < 30\%$) was not found among these articles; thus fixed effect model was applied in this meta-analysis. As shown in Figure 3, the results indicated that CKI combined with chemotherapeutic drugs had an advantage of improving life...
tochemotherapeutic drugs alone. That CKI combined with chemotherapeutic drugs is superior to chemotherapy for advanced colon cancer patients. It also significantly improved (OR = 1.90, 95% CI: 1.11–3.25) in CKI combined with chemotherapeutic drugs group. It further strengthened the evidence that CKI could reduce the adverse events of chemotherapy drugs. However, the evidence is limited, and further trials are required to confirm our findings.

Colon cancer had an upward trend of the incidence worldwide [47]. Although surgical treatment has made great progress, the five-year overall survival of colon cancer is still hovering around 50% [48]. In recent years, chemotherapy can prolong the lives of patients and improve the patients’ quality of life [49]; nevertheless, the commonly chemotherapeutic regimens often seriously impair the life quality of the patients and cause serious constraints on the use of chemotherapeutic drugs. It is urgent to seek more optimized combination chemotherapy. CKI plus chemotherapeutic drugs has been widely used for patients with tumors in China for decades. Our subgroup meta-analysis suggested that CKI plus chemotherapeutic drugs could significantly reduce adverse reaction such as nausea and vomiting (OR = 0.48, 95% CI: 0.32–0.70), leucopenia (OR = 0.55, 95% CI: 0.35–0.84), and thrombocytopenia (OR = 0.61, 95% CI: 0.37–1.00) except for liver function damage (OR = 0.85, 95% CI: 0.51–1.44). Furthermore, the quality of life was also significantly improved (OR = 1.90, 95% CI: 1.11–3.25) in CKI combined with chemotherapeutic drugs group. It further strengthened the evidence that CKI could reduce the adverse events of chemotherapy drugs. However, the evidence is limited, and further trials are required to confirm our findings.

As we know, the development and prognosis of malignant tumor are closely related to immune function. T lymphocytes play an important role in the immune system. Sensitized T lymphocytes have specific killing effect on tumor cells. CD4+ T helper cells coordinate B cell differentiation to produce antibody. CD8+ cells could inhibit the synthesis, secretion of antibodies, and proliferation of T cells. The level or proportion of T cell subsets change will cause some changes of immune function. Published studies suggested that active ingredient matrine in CKI can improve the immune function and prolong the survival of patients [18, 50, 51]. Kang et al.
demonstrated that the immune function and life quality were significantly improved in patients with advanced colon cancer by CKI plus chemotherapeutic drugs treatment [33, 38]. CD3+, CD4+, and CD4+/CD8+ T lymphocytes percentage was not significantly changed in CKI plus chemotherapeutic drugs, while CD3+, CD4+, and CD4+/CD8+ T lymphocytes percentage significantly decreased after chemotherapeutic drugs alone treatment. The concentrations of IL-2 and TNF-α also play an important role in the immune function, which may enhance the ability of tumor controlling for cancer patients [37, 41]. Li et al. proved that CKI plus chemotherapeutic drugs not only can significantly improve the clinical efficacy of patients with advanced colon cancer but also can regulate the immune system function such as increasing the serum level of IL-2, TNF-α, and TNF-γ [31]. However, as eligible trials were limited, we did not evaluate the effect of CKI combined with chemotherapeutic drugs on immune function of patients with advanced colon cancer in this meta-analysis.

There are several limitations to this study, which need to be concerned. First, although we retrieved current online databases including PubMed, Cochrane, CNKI, CBM, and Wan-Fang Database in China without language restrictions, all the included articles relating to CKI combined with chemotherapeutic drugs versus chemotherapeutic drugs alone for advanced colon cancer patients were only found.
in China, which indicated that publication bias might exist across studies. Secondly, we found that CKI combined with chemotherapeutic drugs had beneficial effects in the improvement of efficacy and safety in patients with advanced colon cancer. However, the quality of the included RCTs was not high and had relatively small cases, which might cause some bias. Future research should focus on methodologically strong RCTs to determine the potential efficacy of CKI. Thirdly, it was not an individual patient data analysis, and meta-analyses based on published data tended to overestimate treatment effects compared with individual patient data analysis [52]. In addition, the included study lacked a more comprehensive analysis such as adjusting for baseline factors and other differences that existed between the studies from which the data was pooled. Fourthly, though in this study we did not found significant heterogeneity, the chemotherapy regimen and duration of CKI treatment were inconsistent between studies, which increased the risk of heterogeneity. In addition, most of the included studies were performed at hospital among patients with major organ function normal; thus the results may not entirely apply to the general patient population in the community or patients with organ damaged or dysfunction.

On the other hand, there are some highlights in our study. Our meta-analysis systematically and comprehensively examined the efficacy and safety of CKI combined with chemotherapeutic drugs on patients with advanced colon cancer. The favorable treatment of CKI in combination with chemotherapeutic drugs may be highly meaningful for patients with advanced colon cancer. Furthermore, due to comprehensive analysis of all eligible studies, our meta-analysis increases the power and plausibility of the conclusion when compared with previous individual studies.

5. Conclusion

In summary, although the quality of the eligible studies is not sufficient, our findings are helpful for clinical practice and treatment for advanced colon cancer. CKI combined with chemotherapeutic drugs is favorable to improve the efficacy and quality of life and increase the safety by reducing the incidence of nausea, vomiting, thrombocytopenia, and leucopenia in patients with advanced colon cancer. However, high-quality studies should be conducted to confirm our findings.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by the research grant from National Natural Science Foundation of China (81503427).

References

[1] P. Favoriti, G. Carbone, M. Greco, F. Pirozzi, R. E. M. Pirozzi, and E. Corcione, “Worldwide burden of colorectal cancer: a review,” Updates in Surgery, vol. 68, no. 1, pp. 7–11, 2016.
[2] P. Boyle and J. S. Langman, “ABC of colorectal cancer: Epidemiology,” British Medical Journal, vol. 321, no. 7269, pp. 805–808, 2000.
[3] M. L. McCullough, A. S. Robertson, A. Chao et al., “A prospective study of whole grains, fruits, vegetables and colon cancer risk,” Cancer Causes & Control, vol. 14, no. 10, pp. 959–970, 2003.
[4] P. A. Kurup, N. Jayakumari, M. Indira et al., “Diet, nutrition intake, and metabolism in populations at high and low risk for colon cancer. Composition, intake, and excretion of fiber constituents,” American Journal of Clinical Nutrition, vol. 40, no. 4, pp. 942–946, 1984.
[5] P. Siler, S. D’Ugo, D. Benavoli et al., “Metachronous splenic metastasis from colonic carcinoma five years after surgery: A case report and literature review,” Southern Medical Journal, vol. 102, no. 7, pp. 733–735, 2009.
[6] X. L. Fang, “Study the curative effect of advanced stage colon carcinoma treated by LOHP combined with 5-FU/CF,” Chinese Journal of Clinical Rational Drug Use, vol. 2, no. 8, 2009.

[7] C.-S. Lu, P.-Y. Chang, Y.-G. Chen, J.-H. Chen, Y.-Y. Wu, and C.-L. Ho, “Stage III colon cancer: The individualized strategy of adjuvant chemotherapy for aged under and over 70,” PLoS ONE, vol. 10, no. 9, Article ID e0138632, 2015.

[8] F. A. Sinicrope, M. R. Mahoney, T. C. Smyrk et al., “Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy,” Journal of clinical oncology: official journal of the American Society of Clinical Oncology, vol. 31, no. 29, pp. 3664–3672, 2013.

[9] T. Masuda, K. Nagai, and K. Sanada, “A Case of Drug-Induced Thrombocytopenia Resulting from Sensitivity to Oxaliplatin,” Gan to kagaku ryoho. Cancer & chemotherapy, vol. 42, no. 12, pp. 2157–2159, 2015.

[10] Y. S. Park, J. Ji, J. R. Zalckberg, M. El-Serafi, A. Buzaid, and M. Ghosn, “Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCEx registry,” Asia-Pacific Journal of Clinical Oncology, vol. 11, no. 4, pp. 334–342, 2015.

[11] M.-L. Liu, L.-Y. Chien, C.-J. Tai, K.-C. Lin, and C.-J. Tai, “Effectiveness of traditional Chinese medicine for liver protection and chemotherapy completion among cancer patients,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 291843, 8 pages, 2011.

[12] B. Hu, S.-S. Wang, and Q. Du, “Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: from bench to bedside,” World Journal of Hepatology, vol. 7, no. 9, pp. 1209–1232, 2015.

[13] F. Qi, L. Zhao, A. Zhou et al., “The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer,” Bioscience Trends, vol. 9, no. 1, pp. 16–34, 2015.

[14] M. S. Bai, Z. P. Wu, and X. C. Wang, “Advances in research on adjuvant effects applying Traditional Chinese Medicine in cancer chemotherapy,” Journal of Modern Oncology, vol. 18, no. 3, pp. 597–601, 2010.

[15] J. Li, H. S. Lin, and W. Hou, “Idea and strategy of traditional Chinese medicine treatment for cancer,” Chinese Journal of Cancer, vol. 28, no. 1, pp. 70–76, 2010.

[16] Y. Guo, Y. Huang, H. Shen et al., “Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 840742, 8 pages, 2015.

[17] J. Tian, W.-H. Wang, H.-M. Cao, and Z.-M. Wang, “Determination of matrine, sophoridine and oxymatrine in compound Kushen injection by HPLC,” Zhongguo Zhongyao Zazhi, vol. 32, no. 3, pp. 222–224, 2007.

[18] W. Wang, R. L. You, W. J. Qin et al., “Anti-tumor activities of active ingredients in Compound Kushen Injection,” Acta Pharmacologica Sinica, vol. 36, no. 6, pp. 667–679, 2015.

[19] L. Qi, J. Zhang, and Z. Zhang, “Determination of four alkaloids in compound Kushen Injection by high performance liquid chromatography with ionic liquid as mobile phase additive,” Chinese Journal of Chromatography, vol. 31, no. 3, pp. 249–253, 2013.

[20] L. M. Xia, “Clinical research progress of Compound Kushen Injection in treatment of malignant tumor,” Journal of Clinical Oncology and Rehabilitation, vol. 18, no. 4, pp. 365–367, 2011.

[21] Q. Sun, W. Ma, Y. Gao, W. Zheng, B. Zhang, and Y. Peng, “Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 9, no. 2, pp. 178–188, 2012.

[22] Y. Y. Wu, V. C. H. Chung, P. Lu et al., “Chinese herbal medicine for improving quality of life among nonsmall cell lung cancer patients: overview of systematic reviews and network meta-analysis,” Medicine, vol. 95, no. 1, Article ID e2410, pp. 1–12, 2016.

[23] M. Sun, H. Cao, and L. Sun, “Antitumor activities of kushen: literature review,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 375219, 11 pages, 2012.

[24] S.-K. Zhou, R.-L. Zhang, Y.-F. Xu, and T.-N. Bi, “Antioxidant and immunity activities of Fufang Kushen Injection Liquid,” Molecules (Basel, Switzerland), vol. 17, no. 6, pp. 6481–6490, 2012.

[25] S. Zhang, B. Cheng, H. Li et al., “Matrine inhibits proliferation and induces apoptosis of human colon cancer LoVo cells by inactivating Akt pathway,” Molecular Biology Reports, vol. 41, no. 4, pp. 2011–2018, 2014.

[26] C. Chang, S.-P. Liu, C.-H. Fang et al., “Effects of matrine on the proliferation of HT29 human colon cancer cells and its antitumor mechanism,” Oncology Letters, vol. 6, no. 3, pp. 699–704, 2013.

[27] X. S. Wang and B. Liu, “Clinical study of compound kushen injection combined with chemotherapy in the treatment of patients with advanced colon cancer,” Research of Integrated Traditional Chinese and Western Medicine, vol. 7, no. 2, pp. 78–80, 2015.

[28] W. Hou, J. Liu, W.-G. Shi, and H.-S. Lin, “Multi-center, randomized, controlled clinical study of radiation pneumonitis treated with compound matrine injection in primary lung cancer patients,” Chinese Journal of New Drugs, vol. 22, no. 17, pp. 2065–2068, 2013.

[29] C. L. Tao and J. F. Xu, “Effect of compound kushen injection combined with chemotherapy in the treatment of 74 patients with advanced colon cancer,” Guiding Journal of Traditional Chinese Medicine and Pharmacy, vol. 19, no. 11, pp. 42–44, 2013.

[30] X.-Y. Zeng, H. Wang, F. Bai et al., “Identification of matrine as a promising novel drug for hepatic steatosis and glucose intolerance with HSP72 as an upstream target,” British Journal of Pharmacology, vol. 172, no. 17, pp. 4303–4318, 2015.

[31] D. Li, Q. H. Zhang, S. Wu et al., “Clinical study of compound kushen injection combined with chemotherapy in the treatment of patients with advanced colon cancer,” Lijiang Journal of Traditional Chinese Medicine, vol. 42, no. 5, pp. 1021–1022, 2015.

[32] Y. J. Bao, X. Y. Kong, L. P. Yang et al., “Complementary and alternative medicine for cancer pain: an overview of systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 170396, 9 pages, 2014.

[33] T. Kang, L. Min, and D. Wei, “Effect of compound kushen injection combined with conventional chemotherapy in the treatment of colon cancer clinical observation,” Peoples Military Surgeon, vol. 58, no. 11, pp. 1336–1337, 2015.

[34] J. E. Gao and G. Feng, “Compound kushen injection combined with chemotherapeutic drugs in the treatment of 40 cases with advanced colon cancer,” China Pharmacuetic, vol. 23, no. 24, pp. 103–105, 2014.

[35] R. R. Li and H. S. Li, “Effect of compound kushen injection combined with chemotherapy in the treatment of 35 patients...
with advanced colon cancer,” *Tianjin Pharmacy*, vol. 27, no. 4, pp. 50–51, 2015.

[36] X. G. Liu, “Feasibility analysis of compound kushen injection combined with chemotherapy in the treatment of patients with advanced colon cancer,” *Chinese Journal of Modern Drug Application*, vol. 8, no. 19, pp. 150–151, 2014.

[37] H. W. Qi, “Study of compound kushen injection combined with chemotherapy in the treatment of patients with advanced colon cancer,” *Liaoning Journal of Traditional Chinese Medicine*, vol. 43, no. 3, pp. 547–548, 2016.

[38] L. J. Zheng, E. G. Pang, Z. W. Yang, Z. P. Xiong, J. L. Xing, and J. Ma, “Clinical observation of compound kushen injection in the treatment of colon cancer,” *Nei Mongol Journal of Traditional Chinese Medicine*, vol. 30, no. 10, pp. 1–2, 2011.

[39] L. Xu, “The efficacy of compound kushen injection combined with chemotherapy in the treatment of patients with advanced colon cancer,” *Contemporary Medicine Forum*, vol. 12, no. 11, pp. 38–39, 2014.

[40] Z. J. Wang, Z. Zhou, and L. Bai, “Combination of traditional Chinese and Western medicine in the treatment of 66 cases of colon cancer,” *Journal of the Chinese Medical Association*, vol. 31, no. 36, pp. 86–88, 2015.

[41] H. Ren, J. Sun, and L. X. Zhang, “Effect of compound kushen injection combined with chemotherapy in the treatment of colon cancer,” *China Health Care Nutrition*, no. 5, pp. 2468–2469, 2014.

[42] X. G. Fang and K. S. Zhang, “Analysis on the clinical effect of compound Sophora Flavescens injection plus chemotherapy on Terminal Colorectal Cancer,” *Anti-Tumor Pharmacy*, vol. 2, no. 4, pp. 293–294, 2012.

[43] M. Xiang and A. H. Liu, “Effect of compound kushen injection combined with raltitrexed and oxaliplatin for the treatment of advanced colorectal cancer,” *Drugs & Clinic*, vol. 31, no. 1, pp. 84–85, 2016.

[44] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[45] N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” *Journal of the National Cancer Institute*, vol. 22, no. 4, pp. 719–748, 1959.

[46] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” *British Medical Journal*, vol. 315, pp. 629–634, 1997.

[47] J. Tian and J.-S. Chen, “Time trends of incidence of digestive system cancers in change of China during 1988–2002,” *World Journal of Gastroenterology*, vol. 12, no. 28, pp. 4569–4571, 2006.

[48] M. Zippi, G. De Toma, G. Minervini et al., “Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy,” *Saudi Journal of Gastroenterology*, vol. 23, no. 1, pp. 39–44, 2017.

[49] L.-C. Moreau, R. Rajan, M. P. Thirlwell, and T. Alcindor, “Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting,” *Anticancer Research*, vol. 33, no. 4, pp. 1765–1768, 2013.

[50] C. Luo, Y. Zhu, T. Jiang et al., “Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family,” *Toxicology*, vol. 229, no. 3, pp. 245–252, 2007.

[51] W. Ho JW NganHonPl. Chim O, “Effects of oxymatrine from Ku Shen on cancer cells,” *Anticancer Agen-Med Chem*, vol. 9, no. 8, pp. 823–826, 2009.